Clinical Trial VICCNCPED10101
Title
Hematopoietic Cell Transplantation for Treatment of Patients with Primary Immunodeficiencies and Other Nonmalignant Inherited Disorders Using Low-Dose TBI and Fludarabine with or without Campath
Principal Investigator(s)
Details
- Protocol No. VICCNCPED10101
- Open Date: 12/28/2006
- Staging: NA
- Age Group: Both Child and Adult
- Scope: National
- Objective: Improve donor chimerism levels in patients with inherited nonmalignant disorders undergoing HCT using a reduced intensity conditioning regimen either through the addition of Campath or a slightly higher dose of TBI.
- Disease Sites: Pediatrics; Benign Hematologic
- Therapies: Bone Marrow/Stem Cell Transplant; Chemotherapy - cytotoxic; Molecular Targeted Agents / Immunotherapy / Biologics; Radiotherapy
- Drugs: Campath-1H; Fludarabine (Fludara)
- Participating Institutions: Vanderbilt University
- Secondary Protocol No: 2007.00
Description
None Provided.
Eligibility
Not provided. Please call for more information.
Learn More
- Call toll-free number: 1-800-811-8480
- Use our Online self–referral form
- Print this page for your doctor
You do not have JavaScript enabled. This site works better with JavaScript turned on.
